Clinical trial
Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
NCT00404092 · University of Cologne, Other · Completed
Key facts
| NCT number | NCT00404092 |
|---|---|
| Title | Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis |
| Official title | A Phase II Dose Escalation Study of Caspofungin in Patients With Invasive Aspergillosis |
| Lead sponsor | University of Cologne, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Invasive Aspergillosis |
| Intervention type | Drug |
| Interventions | caspofungin |
| Enrollment | 46 |
| Start date | Oct 1, 2006 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Nov 27, 2006 |
| Last update posted | Jul 31, 2013 |
| Countries | Belgium, Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: